Antibody Anti Trpv4 Extracellular, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody anti trpv4 extracellular/product/Alomone Labs
Average 93 stars, based on 2 article reviews
Price from $9.99 to $1999.99
1) Product Images from "Protease Activated Receptor 2 (PAR2) Induces Long-Term Depression in the Hippocampus through Transient Receptor Potential Vanilloid 4 (TRPV4)"
Article Title: Protease Activated Receptor 2 (PAR2) Induces Long-Term Depression in the Hippocampus through Transient Receptor Potential Vanilloid 4 (TRPV4)
Journal: Frontiers in Molecular Neuroscience
Figure Legend Snippet: PAR2 and TRPV4 expression in the hippocampus. Immunohistochemistry discloses the expression of PAR2 and TRPV4 in the hippocampus. A comparable expression pattern is observed: high levels of PAR2 and TRPV4 are detected in CA1 stratum pyramidale (pcl, pyramidal cell layer; oriens, stratum oriens; rad, stratum radiatum; la-mol, stratum lacunosum-moleculare). No pronounced colocalization between PAR2 and GFAP was detected. Scale bars: 100 and 10 μm, n = 9 slices out of three animals.
Techniques Used: Expressing, Immunohistochemistry
Figure Legend Snippet: PAR2 induces LTD through the activation of TRPV4. (A) Application of TRPV4-agonist (2 μM RN1747) causes LTD. (B) Removal of the TRPV4-agonist (2 μM RN1747) following induction of LTD does not affect the stability of synaptic depression. (C) In presence of the TRPV4-antagonist (10 μM RN1734) the TRPV4-agonist is not able to induce synaptic depression. (D) In a two pathways experimental setting, low frequency stimulation (LFS, 1 Hz, 900 pulses) and TRPV4-agonist application induce similar levels of LTD. (E) LFS-induced LTD is not blocked by the TRPV4-antagonist. (F) Application of PAR2-agonist (10 μM AC55541) in presence of a TRPV4-antagonist (10 μM RN1734) blocks PAR2-induced LTD. (G) Application of TRPV4-agonist (2 μM RN1747) in presence of PAR2-antagonist (50 μM FSLLRY-NH 2 ) does not affect TRPV4-induced LTD. (H) Once PAR2-agonist mediated LTD is established, the TRPV4-agonist (2 μM RN1747) does not further de-potentiate a second pathway at adjusted response level (upward arrow). Averaged EPSP are plotted versus time. Representative traces at indicated times (a, b) are shown on top of each section, n = 12 slices for each experiments, refer to text for statistics.
Techniques Used: Activation Assay
Figure Legend Snippet: TRPV4-mediated LTD depends on NMDAR-activity. (A) Similar to PAR2-induced LTD (c.f., Figures 1G,H ), the NMDAR-antagonist (50 μM APV) blocks TRPV4 (2 μM RN1747)-induced LTD, while (B) application of a TRPV4-agonist (2 μM RN1747) induces LTD in presence of the mGluR-antagonist (200 μM MCGP). Averaged EPSP are plotted versus time. Representative traces at indicated times (a, b) are shown on top of each section.
Techniques Used: Activity Assay
2) Product Images from "Expression and Functional Role of TRPV4 in Bone Marrow-Derived CD11c+ Cells"
Article Title: Expression and Functional Role of TRPV4 in Bone Marrow-Derived CD11c+ Cells
Journal: International Journal of Molecular Sciences
Figure Legend Snippet: TRPV4 was downregulated in mature CD11c + BMDCs. ( A ) Concentration dependence of immature (black bars) and mature (dark cyan bars) CD11c + BMDC responding fraction. ***, p
Techniques Used: Concentration Assay
Figure Legend Snippet: TRPV4-deficient BMDCs exhibited impaired FcR-dependent phagocytosis. ( A ) Representative confocal images of wild-type and Trpv4 KO BMDCs after treatment with uncoated or IgG-coated fluorescent microspheres. Scale bar, 20 µm. ( B ) Percentage of cells with internalized beads. Data were collected from 10 randomly selected fields per condition from three independent experiments. ***, p
Figure Legend Snippet: TRPV4 was dispensable in the differentiation of CD11c + BMDCs. ( A ) Color-coded two-dimensional t-distributed stochastic neighbor embedding (tSNE) representations of the total bone marrow-derived cell population (20,000 cells) defined by the surface markers CD11b, CD11c, and F4/80. ( B ) Histograms showing surface expression of the indicated markers in bone marrow-derived cells from wild-type (WT, black traces) and Trpv4 knockout (KO, red traces) mice. The shaded histograms represent specificity (fluorescence minus one) controls. The bar graph shows the percentage of different cell populations present in total bone marrow-derived cell cultures defined by the surface expression of CD11b, CD11c, and F4/80. The data are represented as mean ± SEM of nine independent experiments.
Techniques Used: Derivative Assay, Expressing, Knock-Out, Mouse Assay, Fluorescence
Figure Legend Snippet: TRPV4 was functionally expressed in CD11c + bone marrow-derived cells (BMDCs). ( A ) Expression profile of selected Trp genes in the total granulocyte-macrophage colony-stimulating (GM-CSF)-differentiated bone marrow-derived cell population (black bars) and in CD11c + -purified BMDCs (light gray). Values are relative to GAPDH expression. ( B ) Confocal image of CD11c + BMDCs stained with an anti-TRPV4 antibody (red). The blue color corresponds to nuclear staining with DAPI. ( C–E ) Representative traces of intracellular Ca 2+ concentration in CD11c + BMDCs showing the effects of 300 nM of GSK1016790A (GSK). ATP (100 μM) was used as a positive control for intracellular Ca 2+ increase. The TRPV4 antagonist HC067047 was used at 10 μM. ( F ) Percentage of CD11c + BMDCs responding to the indicated stimulus. GSK, GSK1016790A (300 nM); HC, HC067047 (1 µM); Ca 2+ -free, Krebs with nominal [Ca 2+ ] supplemented with 2.5 mM EDTA; Caps, Capsaicin (1 nM); THC, trans-Δ 9 -tetrahydrocannabinol (10 µM). The responding fraction is indicated within each bar. ***, p
Techniques Used: Derivative Assay, Expressing, Purification, Staining, Concentration Assay, Positive Control
Figure Legend Snippet: LPS-induced cytokine production occurred independently of TRPV4. ( A ) Representative confocal immunofluorescence microscopy images of fixed BMDCs untreated or treated with LPS (100 ng/mL). Cell stainings correspond to NF-κB p65 (red) and DAPI (nuclear, blue). Scale bar, 10 µm. The average linear intensity along the gray rectangle is represented next to the corresponding image. ( B ) Percentage of the total nuclear area stained by NF-κB p65 staining. The horizontal bar represents the mean. ***, p
Techniques Used: Immunofluorescence, Microscopy, Staining